Most of these 36 drugs are just needed at high prices. Compared with the average retail price of 20 16, the negotiated medical insurance payment standard decreased by 44% on average, and the highest reached 70%. Considering the affordability of the medical insurance fund, the burden of patients' medical expenses will be greatly reduced.
Among western medicines, 15 is a tumor treatment drug, covering lung cancer, gastric cancer, breast cancer, colorectal cancer, lymphoma, myeloma and other cancer species. Among them, tumor-targeting drugs such as trastuzumab, rituximab, bortezomib and lenalidomide have attracted much social attention and are urgently needed by the insured.
Other drugs are drugs for treating cardiovascular diseases, nephropathy, eye diseases, psychosis, anti-infection, diabetes and other major diseases or chronic diseases. Two rare drugs are recombinant human coagulation factor ⅶ A for treating hemophilia and recombinant human interferon β- 1b for treating multiple sclerosis.
There are three kinds of tumor drugs and two kinds of cardiovascular and cerebrovascular drugs in Chinese patent medicine. In addition, the negotiation of medical insurance drug list access fully reflects the importance and support for medical innovation, and all the major new drugs included in the negotiation scope, such as Chidamei, Compaxip and Apatinib, have been successfully negotiated. 3 1 among western medicines, there are 22 kinds of imported medicines and 9 kinds of domestic medicines.
It is understood that these drugs have high clinical value but are expensive, and the burden on patients is heavy. For example, the domestic market price of trastuzumab, a targeted drug for breast cancer, 20 16 is about 24,500 yuan/piece. After this negotiation, the payment standard of trastuzumab after entering the medical insurance drug list was reduced to 7600 yuan per unit, a decrease of about 69%. Considering that after entering the category B catalogue, the medical insurance fund will pay more than 70% of the expenses, and the expenses borne by patients will be further reduced. At the same time, the payment standard of most imported drugs after negotiation is lower than the price of the surrounding international market, so patients no longer need to go to neighboring countries and regions to buy drugs to save money.
In February this year, Ministry of Human Resources and Social Security released the 20 17 version of the national drug list of basic medical insurance, industrial injury insurance and maternity insurance. Then, through expert review, 44 relatively high-priced patents and exclusive drugs were identified as negotiating drugs, and medical insurance agencies started negotiations with pharmaceutical companies to determine the appropriate medical insurance payment standards. In the end, 36 of the 44 drugs were successfully negotiated. This new attempt has obviously expanded the scope of protection and effectively controlled the expenditure of medical insurance fund and the burden of social medical expenses. Although the drug prices of pharmaceutical companies have dropped sharply, they will be used more after being included in the catalogue, which is also conducive to the development and innovation of enterprises.